Scancell Share Discussion Threads

[inanaco] 19/6/2024 10:27

this election is fascinating ...

Labour Blue Print is wales .......... FFS

conservative went socialist with the one nation Tories ... rejected by the membership and the country

Labour then Poll higher than the conservatives with the same policy which is growth without the stick of Liz Truss .. but with politics of envy, pretty well impossible because anyone in business will think the tax base is not stable rather than the economy

It now turns out Starmers Dad the toolmaker was Starmers Dad Own Business ...

so Starmer is nearly as unpopular than Rishi ..

and here we are

work that out and we can predict the Shareprice

[inanaco] 19/6/2024 10:20

Lindy said add a zero ........... if you take the MAB to Clinic ready

as your maths is poor Ruck 5 becomes $50m which matches Marcus post

and if you read what i posted ref calculator use ... it mentions more than 5 Mabs

[mikecro2] 19/6/2024 10:11

3444r34 the 20th 63396 hour was out 55 inches 55 inch long before 555555inches and 5.1m the last two weeks o 5.1m then you are saying you have a 5right 55585feet y7

[ruckrover] 19/6/2024 10:10

Marcus,We all watched that last week and had a good discussion around it. Are you getting desperate now?

[ruckrover] 19/6/2024 10:08

I get that. My point was even if shares WERE valued on the basis of underlying value, 5 deals would only be worth 1.6p per share. That is intil the money is spent!

[markingtime] 19/6/2024 09:57

Aaaahhhh....someone foolish enough to play "technical trading"(hah hah :-)))) in a stock which can see step changes of valuation on news events. Love it :-)))And in a sector where there are many events a year which cause such large moves.......Can't wait to see what happens when news drops :-)

[marcusl2] 19/6/2024 08:50

focusIR
@_focusIR_
·
Professor Lindy Durrant, founder of
@scancellpharma
provides a fascinating insight into the company's innovative cancer vaccines.

Watch the full interview here ▶️

[2tyke] 19/6/2024 08:23

Ruckrover,

Stock prices are NOT linear.
And they don't move as a function of any asset the underlying company owns or promises to own.
A stock ticker is traded.
It is driven by the collective psychology of traders as they try to turn a profit. That emotion is currently negative for this stock and has been for a long time. It doesn't matter to them what the company 'have'.
The only thing that will tell us when this changes is the stock price itself. It would need to rise above a certain price level. That is the key.
There is NO other way of determining a change in trader psychology.

[rogerbridge] 19/6/2024 07:51

We now have a commercial team in board, I trust that they will more than earn their salary.

[ruckrover] 19/6/2024 07:50

Yes, 5 times $5M = $25M. We've already had one of the $5M upfront payments so potentially another $20M to the cash pot. That could add 1.6p to the share price.

[ruckrover] 19/6/2024 07:46

"lindy did say it adds a zero !"Maybe she should get some then. Can anyone explain why this deal is 1.2B with an upfront of $55M whereas our GenMab deal was $624M with a paltry $5M upfront?

[inanaco] 19/6/2024 00:23

and just in case anyone can use the "multiply" button ...

These five mAbs are undergoing preclinical characterisation, with target validation underway for a number of other mAbs to add to the growing portfolio.

[inanaco] 18/6/2024 23:12

lindy did say it adds a zero !

[marcusl2] 18/6/2024 22:38

$55 million upfront up to $1.2 billion for exclusive licensing rights to an antibody drug conjugate (ADC)
The ADC nabbed investigational new drug clearance from the FDA in April, which allows for in-human testing. California-based Day One anticipates phase 1 dosing for the first patient to begin in the last quarter of this year or the first quarter of 2025.

[inanaco] 18/6/2024 11:04

Lozan has named his chirpy friend Mbappé

[ruckrover] 17/6/2024 19:08

Lozan,Not too dissimilar actually. We have a blackbird that comes onto the lawn and looks straight through the patio windows and chirps for his mealworm. He won't shut up until we go out with a handful.

[the real lozan] 17/6/2024 18:57

On a happier note....Wildlife -
Half an hour ago,a tiny Chiffchaff smacked into one of our lounge window doors,
Polaxed -
I picked it up gently...it showed life was not completely extinguished
I held it in my hand, gently stroking it's nape and back, with soothing words and clicks... it slowly recovered... and sat peacefully on my arm, for some time.
It then allowed it's self to sit in Mrs Lozan's hand/arm, before it hopped/fluttered back onto my arm.
It then flew onto one of our terrace picnic tables and SANG to us for a few moments
Then flew off into some nearby bushes.
Wildlife..... you cannot beat it's rewards
...
How was your day ???

[supernumerary] 17/6/2024 17:50

Bermuda - yes, it's odd how it nags, isn't it? I laughed out loud when he hit the 'efficacious' roadblock.

One other thing I noted in that presentation is that he said that the Genmab work is going to plan (or words to that effect). Not something that can be taken for granted:



The FDA has slammed the brakes on a trial of MediLink Therapeutics’ BioNTech-partnered antibody-drug conjugate (ADC) that has already seen three fatalities, with the agency citing a risk of “unreasonable and significant risk of illness or injuries.”

The German drugmaker announced in a Securities and Exchange Commission filing this morning that the FDA has placed a phase 1 trial on partial hold over concerns that BNT326/YL202 “may, at higher doses, expose human subjects to unreasonable and significant risk of illness or injuries.”


A slide from BioNTech's presentation at the American Society of Clinical Oncology (ASCO) annual meeting three weeks ago showed that of 54 patients who had received BNT326/YL202 in the phase 1 trial as of Feb. 4., two patients from the fifth dose cohort had died, as well as one in the seventh dose group.

To address the FDA requests, MediLink needs to review the clinical and safety data for BNT326/YL202, BioNTech said in today's filing. This includes “providing additional information in the investigators brochure regarding the safety findings including grade 5 adverse events observed” in both the phase 1 study as well as a phase 2 trial of the ADC which, according to ClinicalTrials.gov, kicked off at the end of last year.

[ ... ]

[marcusl2] 17/6/2024 12:14

Brad Loncar

@bradloncar
·
17m

BiotechTV is expanding. Thrilled to welcome
@ByAmyBrown
today, who will be covering the UK biotech scene!

[bermudashorts] 17/6/2024 11:58

super

Completely agree about 'efficacy' - found it oddly distracting.

[inanaco] 17/6/2024 11:56

depends which patent they use ... Iscib1 or immunobody IMHO

[supernumerary] 17/6/2024 11:34

Nothing much I heard of interest in that presentation, although it's curious that Sath N thinks iscib1+ only has 15 years of patent life left, while LD thinks it's 18. They should get their story straight.

They should both learn to pronounce 'efficacy' - it has the stress on the first syllable not the second. He gets by until he has to say 'efficacious' where he stumbles because (unsurprisingly) he can't sort it out :¬(

[markingtime] 17/6/2024 11:24

The touch is clearly much closer.....10.20-10.60 ish

[nigelpm] 17/6/2024 09:05

Huge bid:offer spread - not sure it really tells us anything but interesting nonetheless.